Effects of ACE Inhibitors or ↓-Blockers in Patients Treated with the Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine in the African-American Heart Failure Trial
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
In the A-HeFT (African-American Heart Failure Trial), treatment of African-American patients with New York Heart Association (NYHA) class III/IV heart failure (HF) with fixed-dose combination (FDC) of isosorbide dinitrate/hydralazine (I/H) reduced mortality and morbidity and improved patient reported functional status compared with standard therapy alone.
To examine the benefit of FDC I/H in subgroups based on baseline drug therapy and to investigate whether ACE inhibitors and/or angiotensin receptor antagonists (angiotensin receptor blockers) [ARBs] or ↓-adrenoceptor antagonists (↓-blockers) provided additional benefit in FDC I/H-treated African-American patients with HF.
The A-HeFT was a double-blind, placebo-controlled study enrolling 1050 patients stabilized on optimal HF therapies and with NYHA class III/IV HF with systolic dysfunction conducted during the years 2001–4 with up to 18 months follow-up. The primary endpoint was a composite of mortality, first HF hospitalization, and improvement of quality of life at 6 months. Secondary endpoints included mortality, hospitalizations, and change in quality of life. Prospective Kaplan-Meier survival analyses were used for differences between FDC I/H and placebo groups and retrospective analyses were conducted within FDC I/H-treated and placebo groups.
Subgroup analysis for mortality, event-free survival (death or first HF hospitalization), and HF hospitalization showed that FDC I/H, compared with placebo, was effective with or without ACE inhibitors or ↓-blockers or other standard medications with all-point estimates favoring the FDC I/H group. Within the placebo-treated group, ↓-blockers or ACE inhibitors and/or ARBs were efficacious in improving survival (hazard ratio [HR] 0.33; p < 0.0001 for ↓-blocker use and HR 0.39; p = 0.01 for ACE inhibitor and/or ARB use). However, within the FDC I/H-treated group, use of ↓-blockers, but not ACE inhibitors and/or ARBs, provided additional significant benefit for survival (HR 0.44; p = 0.029 and HR 0.60; p = 0.34, respectively), event-free survival (HR 0.62; p = 0.034 and HR 0.72; p = 0.29, respectively) and the composite score of death, HF hospitalization and change in quality of life (p = 0.016 and p = 0.13, respectively).
Based on the analysis of baseline medication use in the A-HeFT, FDC I/H was superior to placebo with or without ↓-blockers or ACE inhibitor. However, ↓-blockers but not ACE inhibitors and/or ARBs provided additional significant benefit in African-Americans with HF treated with FDC I/H. These analyses are hypotheses generating and their confirmation in clinical trials needs to be considered.
- Taylor AL, Ziesche S. Yancy C, et al., for the African American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351: 2049–57. CrossRef
- Taylor AL, Ziesche S, Yancy CW, et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation 2007; 115: 1747–53. CrossRef
- Angus DC, Linde-Zwirble WT, Tam SW, et al. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation 2005; 112: 3745–53. CrossRef
- Exner DV, Dries DL, Domanski MJ, et al. Lesser response to angiotensin-converting-enzyme inhibitor therapy in blacks as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344: 1351–7. CrossRef
- Carson P, Ziesche W, Johnson G, et al., for the Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trial. J Card Fail 1999; 5 178–87. CrossRef
- Alderman MH, Cohen HW, Sealey JE, et al. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17: 1–7. CrossRef
- Brewster LM, van Montfrans GA, Kleijnen J. Scientific review: antihypertensive drug therapy in black patients. Ann Intern Med 2004; 141: 614–27.
- Sehgal AR. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension 2004; 43: 566–72. CrossRef
- Bassett Jr DR, Duey WJ, Walker AJ, et al. Racial differences in maximal vasodilatory capacity of forearm resistance vessels in normotensive young adults. Am J Hypertens 1992; 5: 781–6.
- Stein CM, Lanf CC, Nelson R, et al. Vasodilation in black Americans: attenuated nitric-oxide mediated responses. Clin Pharmacol Ther 1997; 62: 436–43. CrossRef
- Cardillo C, Kilcoyne CM, Cannon III RO, et al. Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension 1998; 31: 1235–9. CrossRef
- Cardillo C, Kilcoyne CM, Cannon III RO, et al. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation 1999; 99: 90–5. CrossRef
- Stein CM, Lang CC, Nelson R, et al. Increased vascular adrenergic vasoconstriction and decreased vasodilation in blacks: additive mechanisms leading to enhanced vascular reactivity. Hypertension 2000; 36: 945–51. CrossRef
- Campia U, Choucair WK, Bryant MB, et al. Reduced endothelium-dependent and independent dilation of conductance arteries in African Americans. J Am Coll Cardiol 2002; 40: 754–60. CrossRef
- Li R, Lyn D, Lapu-Bula R, et al. Relaxation of endothelial nitric oxide synthase gene to plasma nitric oxide level, endothelial function and blood pressure in African Americans. Am J Hypertens 2004; 17: 560–7. CrossRef
- Houghton JL, Philbin EF, Strogatz DS, et al. The presence of African American race predicts improvement of coronary endothelial function after supplementary L-arginine. J Am Coll Cardiol 2002; 39: 1314–22. CrossRef
- Kahn DF, Duffy SJ, Tomasian D, et al. Effects of Black race one forearm resistance vessel function. Hypertension 2002; 40: 195–201. CrossRef
- Androne AS, Hryniewicz K, Hudaihed A, et al. Comparison of metabolic vasodilation in response to exercise and ischemia and endothelium dependent flow-mediated dilation in African American versus non-African American patients with chronic heart failure. Am J Cardiol 2006; 97: 685–9. CrossRef
- Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult [online]. Available from URL: http://www.acc.org/clinical/guidelines/failure//index.pdf [Accessed 2007 Aug 16].
- Dries DL, Strong MH, Cooper RS, et al. Efficacy of angio-tensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002; 40: 311–7. CrossRef
- Ghali JK. Race, ethnicity, and heart failure. J Card Fail 2002; 6: 387–9. CrossRef
- Yancy CW, Foweler MB, Colucci WS, et al., For the U.S. Carvedilol Heart Failure Study Group: race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001; 344: 1358–65. CrossRef
- Goldstein S, Deedwania P, Gottlieb S, et al., on behalf of the MERIT-HF Study Group. Metoprolol CR/XL in black patients with heart failure (from the metoprolol CR/XL randomized intervention trial in chronic heart failure). Am J Cardiol 2003; 92: 478–80. CrossRef
- Ghali JK. Beta-blockers in selected heart failure populations. Curr Heart Fail Rep 2005; 2: 100–5. CrossRef
- Liu YH, Xu J, Yang XP, et al. Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure. Hypertension 2002; 39: 375–81. CrossRef
- García-Estaň J, Ortiz MC, O’Valle F, et al. Effects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in rats. Clin Sci 2006; 110: 227–33. CrossRef
- Fujii S, Suzuki Y, Yoshimura T, et al. In vivo three-dimensional EPR imaging of nitric oxide production from isosorbide dinitrate in mice. Am J Physiol 1998; 274: G857–62.
- Münzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase: a new action for an old drug. J Clin Invest 1996; 98: 1465–70. CrossRef
- Dries DL, Exner DV, Gersch BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999; 340: 609–16. CrossRef
- Effects of ACE Inhibitors or ↓-Blockers in Patients Treated with the Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine in the African-American Heart Failure Trial
American Journal of Cardiovascular Drugs
Volume 7, Issue 5 , pp 373-380
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. University Health Center, 2E, Wayne State University, Detroit, MI, 48201, USA
- 2. NitroMed, Inc., Lexington, Massachusetts, USA
- 3. Black Cardiologist Association, Atlanta, Georgia, USA
- 4. University Hospital, University of Colorado, Denver, Colorado, USA
- 5. Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
- 6. Howard University, College of Medicine, Washington, DC, USA